Yazar "Sezer, Tuna" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Can pregnancy-associated plasma protein-A be a marker for the assessment of atherosclerosis risk in patients with chronic plaque psoriasis?
    (Termedia Publishing House Ltd, 2016) Polat, Mualla; Buğdaycı, Güler; Şahin, Aslı; Kaya, Hatice; Sezer, Tuna; Öztürk, Serkan
    Introduction: Psoriasis is an immune-mediated chronic inflammatory dermatosis. Several studies have shown that patients with psoriasis have a much greater risk of cardiovascular diseases than the normal population. The chronic inflammation observed in psoriasis is thought to have a role in the development of atherosclerosis and vascular endothelial injury. Aim: To examine serum pregnancy-associated plasma protein-A (PAPP-A) levels, which has been regarded as a marker of early stage atherosclerosis in patients with psoriasis that do not have concurrent conventional cardiovascular risk markers. Material and methods: Forty-one patients diagnosed with a chronic plaque type of psoriasis and 42 equally matched healthy volunteers were included in this study. The PAPP-A levels were compared between patient and control groups and the association between PAPP-A levels and disease duration and severity were evaluated in the patient group. Results: Statistically, serum PAPP-A levels were significantly higher in the psoriasis group than in the control group (p = 0.015). Serum PAPP-A levels were found to be positively correlated with severity (p = 0.036, r = 0.329) and duration (p = 0.014, r = 0.269) of the disease. Conclusions: As a marker of early stage atherosclerosis, PAPP-A levels were elevated in the psoriasis group and were correlated with disease duration and severity. This elevation reveals the presence of atherosclerosis in patients with psoriasis. Further studies are needed to confirm the use of PAPP-A as an available and inexpensive screening test and cardiovascular risk assessment for all centers.
  • Küçük Resim Yok
    Öğe
    Evaluation of Sense of Smell in Onychomycosis Patients Receiving Terbinafine Treatment
    (Duzce University Medical School, 2021) Polat, Mualla; Karapinar, Tekden; Küçükyangöz, Belgin; Biçer, Yusuf Özgür; Uzun, Özge; Sezer, Tuna
    Aim: The most common side effects of terbinafine are gastrointestinal symptoms. Loss of taste and smell side effects are presented in a small number of case reports. We aimed to measure the effect of terbinafine on the sense of smell and the degree of change in the sense of smell in this study. Material and Methods: Odor identification test (OIT), odor threshold test (OTT), and odor discrimination test (ODT) were applied to the patients treated with terbinafine and the control group. It was applied with “Sniffin Sticks” test pens. Smell test was performed on the patient group just before the start of terbinafine treatment and at the end of 3 months of treatment. Results: There was no statistical difference between the patient and control groups in terms of age (p=0.991) and gender (p=0.811). There was no statistical difference when the initial odor tests of the patient group and the control group were compared. The OIT value of the patient group was 10.15±1.43 at the beginning and 10.10±1.15 at the end of the treatment (p=0.743). The OTT values were 6.23±1.08 at the beginning and 6.21±0.85 at the end of the treatment (p=0.811). The ODT values were 9.71±1.44 at the beginning and 9.69±1.34 at the end of the treatment (p=0.767). There was no statistical difference in the results of the tests performed at the beginning and end of the treatment. Conclusion: There was no adverse effect on the sense of smell associated with the use of systemic terbinafine treatment for 3 months. © 2021, Duzce University Medical School. All rights reserved.